In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
Commentary|Articles|March 6, 2026
From MFN to IRA, Experts Warn of a System Under Pressure in Wide-Ranging Policy Webinar
Author(s)Giuliana Grossi
Fact checked by: Christina Mattina
Experts unpacked MFN drug pricing, expired ACA subsidies, and IRA fallout for community oncology in a recent webinar.
Advertisement
Advertisement
As drug pricing initiatives move forward while coverage policies grow more uncertain, the complexity of the Trump administration’s health care agenda is coming into sharper focus. During a March 3, 2026,
Related to this article
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Advertisement
Advertisement